Biogen Inc (NASDAQ:BIIB) validates its comprehensive approach to challenge multiple sclerosis at the seventh Joint Meeting of the ECTRIMS-ACTRIMS from October 25 to October 28. Michael Ehlers, the EVP of Research & Development at Biogen, expressed that with over 25 years of scientific leadership in Multiple Sclerosis, Biogen’s commitment is firm.
Their expertise puts company in a unique position with a broad approach including dynamic research and clinical development on the way to repair the damage to the CNS from relapsing forms of Multiple Sclerosis, a portfolio of new medicine candidates that they are developing to the clinic, their collaboration to list a digital biomarker, their focus to develop understanding of the disease via international data collection with MS PATHS, active quest of the genetic origins of advanced forms of Multiple Sclerosis, and their innovation in value-based deal pilots in the United States.
The latest from the deal with Women’s Hospital and Verily and Brigham whose objective is to explore the application of digital biosensors to evaluate patients outside of the clinic. More data on the possible use of predictive biomarkers to inform Multiple Sclerosis diagnosis and current disease monitoring, with the objective of helping clinicians with their decisions on the way to cure based on the heterogeneic differences of those struggling with MS, will also be showcased.
Interim reports from MS PATHS, a deal with 10 major MS centers in the U.S. and Europe to use technology executed in routine care to generate standardized, top-quality data from a varied, real-world patient population. MS PATHS gathers clinical, biologic and MRI data from patients at the point of care, in real-time, to better comprehend the disease and ultimately enhance the lives of those struggling with MS. An evaluation of the Big Multiple Sclerosis Data Network, constituted of five MS registries and supported by Biogen.
The network will merge data from large MS registries that have collected longitudinal data on nearly 140,000 people with MS. The scale of this pooled MS data may enable greater understanding of MS and its impact.